Poor Bone Mineral Density Is Associated With Increased Risk of Urological Bone Metastases

Area of Science:

• Urology
• Oncology
• Bone Metabolism

Background:

• Poor bone mineral density (PBMD), encompassing osteopenia and osteoporosis, is a growing concern in patient populations.
• The potential link between PBMD and cancer metastasis, particularly in urological malignancies, requires further investigation.

Purpose of the Study:

• To determine if a diagnosis of precancer poor bone mineral density (PBMD) is associated with an increased risk of bone metastasis in patients with urological cancers.
• To explore the impact of bisphosphonate therapy on bone metastasis risk in this cohort.

Main Methods:

• A retrospective cohort analysis using the PearlDiver Database.
• Propensity-matched analysis of adult patients diagnosed with kidney, bladder, prostate, and testicular cancer, comparing those with and without prior PBMD.
• Comparison of newly diagnosed bone metastases rates between 6 months and 3 years post-cancer diagnosis using odds ratios (OR) and 95% confidence intervals.

Main Results:

• Poor bone mineral density (PBMD) was significantly associated with increased odds of bone metastasis across all studied urological cancers.
• The strongest association between PBMD and bone metastasis was observed within one week of cancer diagnosis.
• Bisphosphonate use was linked to a reduced risk of bone metastasis in kidney, bladder, and prostate cancers.

Conclusions:

• Urology patients with PBMD may have a predisposition to developing bone metastases and may present with metastatic disease at diagnosis.
• Further research is warranted to understand the role of PBMD in bone tropism and its influence on bone metastasis-free survival.